- Home
- DLXY vs MRKR Comparison
DLXY vs MRKR Comparison
Compare DLXY & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLXY
- MRKR
- Stock Information
- Founded
- DLXY 2007
- MRKR N/A
- Country
- DLXY Singapore
- MRKR United States
- Employees
- DLXY N/A
- MRKR N/A
- Industry
- DLXY
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- DLXY
- MRKR Health Care
- Exchange
- DLXY Nasdaq
- MRKR Nasdaq
- Market Cap
- DLXY 13.9M
- MRKR 16.6M
- IPO Year
- DLXY 2025
- MRKR N/A
- Fundamental
- Price
- DLXY $0.96
- MRKR $1.12
- Analyst Decision
- DLXY
- MRKR Strong Buy
- Analyst Count
- DLXY 0
- MRKR 2
- Target Price
- DLXY N/A
- MRKR $10.25
- AVG Volume (30 Days)
- DLXY 61.4K
- MRKR 223.4K
- Earning Date
- DLXY 12-05-2025
- MRKR 11-13-2025
- Dividend Yield
- DLXY N/A
- MRKR N/A
- EPS Growth
- DLXY N/A
- MRKR N/A
- EPS
- DLXY 0.07
- MRKR N/A
- Revenue
- DLXY $314,916,000.00
- MRKR $4,694,988.00
- Revenue This Year
- DLXY N/A
- MRKR N/A
- Revenue Next Year
- DLXY N/A
- MRKR $9.06
- P/E Ratio
- DLXY $15.03
- MRKR N/A
- Revenue Growth
- DLXY 8.90
- MRKR N/A
- 52 Week Low
- DLXY $0.64
- MRKR $0.81
- 52 Week High
- DLXY $7.16
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- DLXY N/A
- MRKR 62.25
- Support Level
- DLXY N/A
- MRKR $0.99
- Resistance Level
- DLXY N/A
- MRKR $1.16
- Average True Range (ATR)
- DLXY 0.00
- MRKR 0.08
- MACD
- DLXY 0.00
- MRKR 0.02
- Stochastic Oscillator
- DLXY 0.00
- MRKR 93.75
About DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.